View Financial HealthOramed Pharmaceuticals 배당 및 자사주 매입배당 기준 점검 2/6Oramed Pharmaceuticals 은(는) 현재 수익률이 6.94% 인 배당금 지급 회사입니다.핵심 정보6.9%배당 수익률3.1%자사주 매입 수익률총 주주 수익률3.1%미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트공시 • Jan 08Oramed Pharmaceuticals Inc. Approves Cash Dividend Payable on January 26, 2026Oramed Pharmaceuticals Inc.'s Board of Directors approved a cash dividend payment of $0.25 per share. The dividend will have an ex-dividend date of January 16, 2026, with disbursement scheduled for January 26, 2026. The dividend is expected to result in an aggregate distribution of approximately $10.5 million based on the current number of shares outstanding. The dividend will be funded with surplus capital.공시 • Nov 18Oramed Pharmaceuticals Inc. Declares Dividend Distribution of Common Stock, Payable on November 27, 2025The Board of Directors of Oramed Pharmaceuticals Inc. announced that it has unanimously adopted a Rights Agreement, dated November 17, 2025 (the "Rights Plan"), by and between the Company and Continental Stock Transfer & Trust Company, as rights agent, and declared a dividend of one common stock purchase right (a "Right") on each outstanding share of its common stock, par value $0.012 per share (the "Common Stock"), of the Company. The dividend distribution will be payable on November 27, 2025, to stockholders of record as of the close of business on November 27, 2025.공시 • Jun 27Oramed Pharmaceuticals Inc. (NasdaqCM:ORMP) announces an Equity Buyback for $20 million worth of its shares.Oramed Pharmaceuticals Inc. (NasdaqCM:ORMP) announces a share repurchase program. Under the program, the company will repurchase up to $20 million worth of its shares. The program will expired in 12 months.모든 업데이트 보기Recent updates공시 • May 17Oramed Pharmaceuticals Inc. announced delayed 10-Q filingOn 05/15/2026, Oramed Pharmaceuticals Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.New Risk • Mar 29New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 189% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (189% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (7.9% average weekly change). Revenue is less than US$5m (US$2.0m revenue).공시 • Mar 26Lifeward Ltd. (NasdaqCM:LFWD) completed the acquisition of Oratech Pharma, Inc. from Oramed Pharmaceuticals Inc. (NasdaqCM:ORMP).Lifeward Ltd. (NasdaqCM:LFWD) entered into a share purchase agreement to acquire Oratech Pharma, Inc. from Oramed Pharmaceuticals Inc. (NasdaqCM:ORMP) on January 12, 2026. At closing, the Company will issue ordinary shares and pre-funded warrants to Oramed Pharmaceuticals, Inc. in an amount representing 49.99% of the Company’s fully diluted equity capitalization, subject to certain adjustments and ownership limitations. The number of ordinary shares issued at closing is capped at 45% of Lifeward’s outstanding ordinary shares, with the balance issued in the form of pre-funded warrants. Approximately 5% of the equity consideration will be held back in the form of pre-funded warrants for indemnification purposes and released after 12 months, subject to claims. In addition, the Company will issue transaction warrants to purchase ordinary shares, with the number of warrants determined by dividing Lifeward’s net cash at closing by an exercise price of $0.45 per share. As further consideration, Lifeward agreed to make contingent quarterly revenue-sharing payments equal to 4% of net revenue from sales of ReWalk Personal Exoskeleton products and related warranties. The transaction is subject to approval by regulatory board / committee, approval of offer by acquirer shareholders, registration statement effectiveness (S-4 / F-4), lock-up agreement and listing / approval of new shares on stock exchange. The transaction has received unanimous approval from Lifeward’s board of directors. The transaction is contingent upon closing conditions. As of March 12, 2026, Lifeward Ltd. shareholders approved the transaction. Rachael M. Bushey and Jennifer Porter of Goodwin Procter LLP acted as legal advisor for Lifeward Ltd. Aaron M. Lampert and Ephraim P. Friedman of Goldfarb Seligman & Co. acted as legal advisor for Lifeward Ltd. Rick A. Werner, Alla Digilova, and Simin Sun of Haynes and Boone, LLP acted as legal advisor for Oramed Pharmaceuticals Inc. Lifeward Ltd. (NasdaqCM:LFWD) completed the acquisition of Oratech Pharma, Inc. from Oramed Pharmaceuticals Inc. (NasdaqCM:ORMP) on March 25, 2026. At closing, Lifeward issued an aggregate 2,256,476 shares of its ordinary shares and pre-funded warrants. Lifeward also issued 1,296,296 warrants to purchase Oratech Pharma's ordinary shares.Valuation Update With 7 Day Price Move • Jan 08Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₪10.58, the stock trades at a trailing P/E ratio of 3x. Average trailing P/E is 24x in the Pharmaceuticals industry in Asia. Total returns to shareholders of 19% over the past three years.공시 • Jan 08Oramed Pharmaceuticals Inc. Approves Cash Dividend Payable on January 26, 2026Oramed Pharmaceuticals Inc.'s Board of Directors approved a cash dividend payment of $0.25 per share. The dividend will have an ex-dividend date of January 16, 2026, with disbursement scheduled for January 26, 2026. The dividend is expected to result in an aggregate distribution of approximately $10.5 million based on the current number of shares outstanding. The dividend will be funded with surplus capital.공시 • Jan 01Oramed Pharmaceuticals Inc. Announces Resignation of Leonard Sank from the Board, Effective as of January 1, 2026On December 31, 2025, the board of directors (the “Board”) of Oramed Pharmaceuticals Inc. (the “Company”) received notice of Leonard Sank’s intention to resign from the Board, effective as of January 1, 2026. Mr. Sank’s resignation did not result from any disagreement with the Company on any matter relating to the Company’s operations, policies or practices. Mr. Sank served 18 years at the Company.Valuation Update With 7 Day Price Move • Dec 14Investor sentiment improves as stock rises 20%After last week's 20% share price gain to ₪10.33, the stock trades at a trailing P/E ratio of 2.8x. Average forward P/E is 20x in the Pharmaceuticals industry in Asia. Total loss to shareholders of 62% over the past three years.New Risk • Nov 19New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Israeli stocks, typically moving 6.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (135% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (6.1% average weekly change). Revenue is less than US$5m (US$2.0m revenue). Market cap is less than US$100m (₪324.5m market cap, or US$99.1m).공시 • Nov 18Oramed Pharmaceuticals Inc. Declares Dividend Distribution of Common Stock, Payable on November 27, 2025The Board of Directors of Oramed Pharmaceuticals Inc. announced that it has unanimously adopted a Rights Agreement, dated November 17, 2025 (the "Rights Plan"), by and between the Company and Continental Stock Transfer & Trust Company, as rights agent, and declared a dividend of one common stock purchase right (a "Right") on each outstanding share of its common stock, par value $0.012 per share (the "Common Stock"), of the Company. The dividend distribution will be payable on November 27, 2025, to stockholders of record as of the close of business on November 27, 2025.공시 • Jul 17Oramed Pharmaceuticals Inc., Annual General Meeting, Aug 19, 2025Oramed Pharmaceuticals Inc., Annual General Meeting, Aug 19, 2025. Location: proskauer rose llp, one boca place, 2255 glades road, suite 421 atrium, fl 33431-7360, boca raton United StatesBoard Change • Jul 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 7 highly experienced directors. Member of Scientific Advisory Board Anne Peters was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.New Risk • Apr 06New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Israeli stocks, typically moving 8.0% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.0% average weekly change). Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable next year (US$2.8m net loss next year). Market cap is less than US$100m (₪321.2m market cap, or US$85.8m).New Risk • Mar 29New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next year. Trailing 12-month net loss: US$19m Forecast net loss in 1 year: US$4.7m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable next year (US$4.7m net loss next year). Share price has been volatile over the past 3 months (7.7% average weekly change). Market cap is less than US$100m (₪329.4m market cap, or US$89.1m).Valuation Update With 7 Day Price Move • Mar 09Investor sentiment improves as stock rises 25%After last week's 25% share price gain to ₪9.16, the stock trades at a trailing P/E ratio of 23.2x. Average forward P/E is 18x in the Pharmaceuticals industry in Asia. Total loss to shareholders of 69% over the past three years.New Risk • Feb 12New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Israeli stocks, typically moving 5.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 104% per year for the foreseeable future. High level of non-cash earnings (40% accrual ratio). Revenue is less than US$1m. Minor Risk Share price has been volatile over the past 3 months (5.8% average weekly change).Valuation Update With 7 Day Price Move • Feb 12Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₪9.34, the stock trades at a trailing P/E ratio of 23.5x. Average forward P/E is 18x in the Pharmaceuticals industry in Asia. Total loss to shareholders of 75% over the past three years.New Risk • Aug 17New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 188% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.9% average weekly change). Earnings are forecast to decline by an average of 198% per year for the foreseeable future. High level of non-cash earnings (188% accrual ratio). Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (₪348.7m market cap, or US$95.1m).New Risk • Jul 31New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₪371.5m (US$98.7m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.7% average weekly change). Earnings are forecast to decline by an average of 169% per year for the foreseeable future. Revenue is less than US$1m (US$674k revenue). Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (₪371.5m market cap, or US$98.7m).Valuation Update With 7 Day Price Move • Jun 27Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₪9.79, the stock trades at a trailing P/E ratio of 10x. Average forward P/E is 18x in the Pharmaceuticals industry in Asia. Total loss to shareholders of 77% over the past three years.공시 • Jun 27Oramed Pharmaceuticals Inc. (NasdaqCM:ORMP) announces an Equity Buyback for $20 million worth of its shares.Oramed Pharmaceuticals Inc. (NasdaqCM:ORMP) announces a share repurchase program. Under the program, the company will repurchase up to $20 million worth of its shares. The program will expired in 12 months.공시 • Jun 22Oramed Pharmaceuticals Inc., Annual General Meeting, Aug 01, 2024Oramed Pharmaceuticals Inc., Annual General Meeting, Aug 01, 2024. Location: 20 mamilla avenue, israel 9414904, jerusalem Israel공시 • Jun 13+ 1 more updateOramed Pharmaceuticals Inc. Appoints Mr. Avraham Gabay as Treasurer and Secretary, Effective as of June 18, 2024On June 6, 2024, Oramed Pharmaceuticals Inc. appointed Mr. Avraham Gabay to serve as Treasurer and Secretary of the Company, effective as of June 18, 2024. Prior to his appointment, Mr. Gabay served as interim chief financial officer of BiomX Inc. since 2023. From 2021 until 2023, Mr. Gabay served as the chief financial officer at Oravax Inc., a 63% owned subsidiary of the Company. From 2019 until 2021, Mr. Gabay was the chief financial officer of the Company. From 2015 to 2019, Mr. Gabay served as VP Finance at Orcam Technologies Ltd. From 2014 to 2015, Mr. Gabay provided economic services in the advisory department of KPMG Israel, a certified public accounting firm, and from 2013 to 2014, he worked in the tax department of the law firm Gornitzky & Co. In addition, Mr. Gabay serves as a director on the board of Iintoo Ltd. Mr. Gabay holds a bachelor’s degree in law and accounting (magna cum-laude) from Tel-Aviv University and is a certified public accountant in Israel and a member of the Israeli Bar Association.New Risk • May 20New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 95% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.5% average weekly change). Earnings are forecast to decline by an average of 95% per year for the foreseeable future. Revenue is less than US$1m (US$674k revenue). Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (₪345.9m market cap, or US$93.4m).Reported Earnings • May 12First quarter 2024 earnings released: EPS: US$0.038 (vs US$0.085 loss in 1Q 2023)First quarter 2024 results: EPS: US$0.038 (up from US$0.085 loss in 1Q 2023). Net income: US$1.54m (up US$4.93m from 1Q 2023). Over the last 3 years on average, earnings per share has increased by 46% per year but the company’s share price has fallen by 36% per year, which means it is significantly lagging earnings.New Risk • Apr 16New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₪369.9m (US$98.1m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risks Large one-off items impacting financial results. Revenue is less than US$5m (US$1.3m revenue). Market cap is less than US$100m (₪369.9m market cap, or US$98.1m).공시 • Mar 19Oramed Pharmaceuticals Inc. has filed a Follow-on Equity Offering in the amount of $75 million.Oramed Pharmaceuticals Inc. has filed a Follow-on Equity Offering in the amount of $75 million. Security Name: COMMON STOCK Security Type: Common Stock Transaction Features: At the Market OfferingReported Earnings • Mar 07Full year 2023 earnings released: EPS: US$0.14 (vs US$0.94 loss in FY 2022)Full year 2023 results: EPS: US$0.14 (up from US$0.94 loss in FY 2022). Net income: US$5.53m (up US$42.1m from FY 2022). Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings.New Risk • Jan 31New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Israeli stocks, typically moving 9.2% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.2% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable next year (US$11m net loss next year). Shareholders have been diluted in the past year (3.1% increase in shares outstanding). Revenue is less than US$5m (US$2.0m revenue).Board Change • Jan 23Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 5 highly experienced directors. Member of Scientific Advisory Board Jay Skyler was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.공시 • Dec 19Oramed Pharmaceuticals Inc. Appoints Daniel Aghion as Director, Effective January 1, 2024On December 18, 2023, Oramed Pharmaceuticals Inc. (Company) increased the size of its Board of Directors by one and appointed Dr. Daniel Aghion to serve as a director to fill the resulting vacancy, effective as of January 1, 2024. The Board has not yet taken action to appoint Dr. Aghion to any committees of the Board. Dr. Daniel Aghion, age 42, is a neurosurgeon at Memorial Neuroscience Institute in Florida since 2016, where he treats patients with a wide array of spine disorders, including severe degenerative spine diseases, spine trauma, cancer in the spine, spine tumors, peripheral nerve surgery and more. Dr. Aghion holds a Bachelor's of Science degree from the University of Michigan and an MD from the Sackler School of Medicine at Tel Aviv University. He completed his residency at Rhode Island Hospital in 2015, and a complex spine fellowship at Johns Hopkins University in Baltimore in 2016.Reported Earnings • Nov 11Third quarter 2023 earnings released: US$0.08 loss per share (vs US$0.18 loss in 3Q 2022)Third quarter 2023 results: US$0.08 loss per share (improved from US$0.18 loss in 3Q 2022). Net loss: US$3.22m (loss narrowed 54% from 3Q 2022). Revenue is expected to decline by 70% p.a. on average during the next 2 years, while revenues in the Pharmaceuticals industry in Asia are expected to grow by 11%. Over the last 3 years on average, earnings per share has remained flat whereas the company’s share price has fallen by 5% per year.New Risk • Oct 05New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₪357.4m (US$93.0m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 21% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$47m net loss in 3 years). Share price has been volatile over the past 3 months (6.8% average weekly change). Shareholders have been diluted in the past year (3.7% increase in shares outstanding). Revenue is less than US$5m (US$2.7m revenue). Market cap is less than US$100m (₪357.4m market cap, or US$93.0m).Reported Earnings • Aug 11Second quarter 2023 earnings released: US$0.03 loss per share (vs US$0.27 loss in 2Q 2022)Second quarter 2023 results: US$0.03 loss per share (improved from US$0.27 loss in 2Q 2022). Net loss: US$1.19m (loss narrowed 89% from 2Q 2022). Revenue is expected to decline by 84% p.a. on average during the next 3 years, while revenues in the Pharmaceuticals industry in Asia are expected to grow by 9.8%. Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has only fallen by 3% per year, which means it has not declined as severely as earnings.공시 • Aug 09Oramed Pharmaceuticals Inc. (NasdaqCM:ORMP) entered into a Stalking Horse Stock Purchase Term Sheet to acquire a 40.17% stake in Scilex Holding Company (NasdaqCM:SCLX) from Sorrento Therapeutics, Inc. (OTCPK:SRNE.Q) for approximately $110 million.Oramed Pharmaceuticals Inc. (NasdaqCM:ORMP) entered into a Stalking Horse Stock Purchase Term Sheet to acquire a 40.17% stake in Scilex Holding Company (NasdaqCM:SCLX) from Sorrento Therapeutics, Inc. (OTCPK:SRNE.Q) for approximately $110 million on August 4, 2023. Oramed Pharmaceuticals Inc. entered into a Stalking Horse Agreement to acquire a 40.17% stake in Scilex Holding Company from Sorrento Therapeutics, Inc. on August 8, 2023. Oramed to purchase 59,726,737 shares of common stock of Scilex and 29,057,096 shares of Series A preferred stock of Scilex under the transaction. As a part of consideration, Oramed will provide a non-amortizing super-priority debtor-in-possession term loan financing facility in an aggregate principal amount of $100 million (the “Replacement DIP Facility”) and remaining consideration in cash. Oramed Pharmaceuticals Inc. will receive a a break-up fee in the amount of $3,412,500, in case of termmination. Oramed will be capitalized with sufficient debt and equity capital to fund the cash portion of the Purchase Price. Term Sheet is subject to a final definitive documentation to be negotiated in good faith between the parties, uthorization and approval by the United States Bankruptcy Court for the Southern District of Texas,all HSR filing and waiting periods applicable to the Sale shall have expired or been terminated, all other governmental and regulatory approvals, if any, shall have been obtained, parties shall have entered into a new Registration Rights Agreement, approval of board of directors of Scilex and satisfaction or waiver of the other Closing Conditions. The proposed transaction will not be subject to a financing contingency. The stalking horse agreement with Oramed is subject to an auction and the submission of higher or otherwise better offers. Any parties interested in bidding for the Scilex Stock should email Sorrento's investment banker (Moelis & Company LLC) as soon as possible to indicate their interest and discuss required bid materials. To the extent Sorrento receives any qualified bids that are higher or otherwise better than Oramed's bid by August 11, 2023, at 5:00 p.m. (ET), Sorrento will hold an auction for the Scilex Stock on August 14, 2023. The U.S. Bankruptcy Court for the Southern District of Texas (the "Bankruptcy Court") approved the transaction on August 8, 2023. Transaction is expected to be completed by or before September 15, 2023. Latham & Watkins LLP and Jackson Walker LLP are serving as legal counsel to Sorrento. M3 Partners is serving as restructuring advisor. Moelis & Company LLC is serving as financial advisor and investment banker. H.C. Wainwright & Co. acted as financial and capital markets advisor to Oramed.공시 • Jul 12Oramed Pharmaceuticals Inc., Annual General Meeting, Jul 13, 2023Oramed Pharmaceuticals Inc., Annual General Meeting, Jul 13, 2023, at 16:00 Israel Standard Time. Location: 20 Mamilla Avenue Jerusalem Israel Agenda: To consider and re-elect six directors of the Company to hold office until next annual meeting of stockholders and until their respective successors shall be elected and qualified or until their earlier resignation or removal; to consider and ratify the appointment of Kesselman & Kesselman, certified public accountants in Israel, a member of PricewaterhouseCoopers International Limited as the independent registered public accounting firm of the Company for the 2023 fiscal year; and to transact any other business as may properly come before the Annual Meeting or any adjournments thereof.Reported Earnings • May 13First quarter 2023 earnings released: US$0.085 loss per share (vs US$0.27 loss in 1Q 2022)First quarter 2023 results: US$0.085 loss per share (improved from US$0.27 loss in 1Q 2022). Net loss: US$3.40m (loss narrowed 67% from 1Q 2022). Revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Asia. Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has only fallen by 3% per year, which means it has not declined as severely as earnings.Recent Insider Transactions • Apr 06Independent Director recently bought ₪70k worth of stockOn the 4th of April, Arie Mayer bought around 9k shares on-market at roughly ₪7.94 per share. This transaction amounted to 49% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger purchase from another insider worth ₪729k. Insiders have collectively bought ₪406k more in shares than they have sold in the last 12 months.Recent Insider Transactions • Mar 16Independent Director recently bought ₪513k worth of stockOn the 14th of March, Yadin Rozov bought around 70k shares on-market at roughly ₪7.33 per share. This transaction increased Yadin's direct individual holding by 4x at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought ₪211k more in shares than they have sold in the last 12 months.Reported Earnings • Mar 08Full year 2022 earnings released: US$0.94 loss per share (vs US$0.94 loss in FY 2021)Full year 2022 results: US$0.94 loss per share. Net loss: US$36.6m (loss widened 4.4% from FY 2021). Revenue is forecast to grow 26% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Pharmaceuticals industry in Asia.공시 • Jan 12Oramed Pharmaceuticals Inc. Announces Top-Line Results from Phase 3 Trial of ORMD-0801 for the Treatment of Type 2 DiabetesOramed Pharmaceuticals Inc. announced top-line results from its Phase 3 randomized, double-blind, placebo-controlled, multicenter clinical trial (ORA-D-013-1) comparing the efficacy of ORMD-0801 to placebo in patients with Type 2 Diabetes (T2D) at 26 weeks. ORA-D-013-1 enrolled 710 patients with T2D and inadequate glycemic control on two or three oral glucose-lowering agents. The ORA-D-013-1 trial did not meet its primary endpoint, which compared the efficacy of ORMD-0801 to placebo in improving glycemic control as assessed by the mean change from baseline in A1C at 26 weeks. The trial also did not meet its secondary endpoint, which assessed the mean change from baseline in fasting plasma glucose at 26 weeks. There were no serious drug-related adverse events. Therefore, Oramed expects to discontinue its oral insulin clinical activities for T2D. Additional Information About the ORA-D-013-1 Phase 3 Clinical Trial: In the ORA-D-013-1 trial, patients were randomized 2:2:1:1 into four groups: 8 mg dosed once-daily; 8 mg dosed twice-daily; placebo dosed once-daily; and placebo dosed twice-daily. Patients completed an initial 21-day Screening Period, followed by a 26-week Double-Blind Treatment Period.공시 • Jan 05Oramed Pharmaceuticals Inc. Granted U.S. Combination Therapy Patent for Oral Glp-1 & Insulin for the Treatment of DiabetesOramed Pharmaceuticals Inc. announced that the United States Patent and Trademark Office has granted the Company a patent titled "Methods and Compositions for Treating Diabetes." The patent serves as an extension to a patent previously granted in May 2022 and addresses methods and compositions for treating diabetes mellitus through oral pharmaceutical compositions comprising insulin in combination with Glucagon-like Peptide 1 (GLP-1).Board Change • Nov 16High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 2 experienced directors. 5 highly experienced directors. Chief Scientific Officer & Director Miriam Kidron is the most experienced director on the board, commencing their role in 2006. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.Reported Earnings • Nov 12Third quarter 2022 earnings released: US$0.18 loss per share (vs US$0.21 loss in 3Q 2021)Third quarter 2022 results: US$0.18 loss per share. Net loss: US$7.06m (loss widened 3.0% from 3Q 2021). Revenue is forecast to grow 86% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Asia.Reported Earnings • Aug 11Second quarter 2022 earnings released: US$0.27 loss per share (vs US$0.17 loss in 2Q 2021)Second quarter 2022 results: US$0.27 loss per share (down from US$0.17 loss in 2Q 2021). Net loss: US$10.5m (loss widened 102% from 2Q 2021). Over the next year, revenue is forecast to grow 6.4%, compared to a 24% growth forecast for the industry in Israel. Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has increased by 38% per year, which means it is well ahead of earnings.Board Change • Jul 15High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 2 experienced directors. 5 highly experienced directors. Chief Scientific Officer & Director Miriam Kidron is the most experienced director on the board, commencing their role in 2006. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.Reported Earnings • May 14First quarter 2022 earnings released: US$0.27 loss per share (vs US$0.17 loss in 1Q 2021)First quarter 2022 results: US$0.27 loss per share (down from US$0.17 loss in 1Q 2021). Net loss: US$10.4m (loss widened 126% from 1Q 2021). Over the next year, revenue is forecast to grow 2.5%, compared to a 23% growth forecast for the industry in Israel. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has increased by 6% per year, which means it is well ahead of earnings.Reported Earnings • Apr 02Full year 2021 earnings released: US$0.94 loss per share (vs US$0.90 loss in FY 2020)Full year 2021 results: US$0.94 loss per share (down from US$0.90 loss in FY 2020). Net loss: US$35.0m (loss widened 59% from FY 2020). Over the next year, revenue is forecast to grow 1.4%, compared to a 21% growth forecast for the pharmaceuticals industry in Israel. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has increased by 30% per year, which means it is tracking significantly ahead of earnings growth.Recent Insider Transactions • Mar 29Independent Chairman of the Board recently sold ₪303k worth of stockOn the 21st of March, Kevin Rakin sold around 10k shares on-market at roughly ₪30.28 per share. This was the largest sale by an insider in the last 3 months. Kevin has been a seller over the last 12 months, reducing personal holdings by ₪1.7m.Reported Earnings • Jan 12First quarter 2022 earnings: EPS in line with expectations, revenues disappointFirst quarter 2022 results: US$0.21 loss per share (up from US$0.23 loss in 1Q 2021). Net loss: US$7.89m (loss widened 42% from 1Q 2021). Revenue missed analyst estimates by 3.7%. Over the next year, revenue is forecast to grow 2.2%, compared to a 22% growth forecast for the industry in Israel. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has increased by 45% per year, which means it is tracking significantly ahead of earnings growth.Reported Earnings • Nov 25Full year 2021 earnings: EPS in line with expectations, revenues disappointFull year 2021 results: US$0.78 loss per share (down from US$0.56 loss in FY 2020). Net loss: US$22.2m (loss widened 93% from FY 2020). Revenue missed analyst estimates by 9.2%. Over the next year, revenue is forecast to stay flat compared to a 23% growth forecast for the pharmaceuticals industry in Israel. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has increased by 62% per year, which means it is tracking significantly ahead of earnings growth.Recent Insider Transactions • Sep 22Independent Chairman of the Board recently sold ₪1.4m worth of stockOn the 16th of September, Kevin Rakin sold around 21k shares on-market at roughly ₪67.43 per share. This was the largest sale by an insider in the last 3 months. This was Kevin's only on-market trade for the last 12 months.Executive Departure • Sep 03Independent Director Xiaoming Gao has left the companyOn the 30th of August, Xiaoming Gao's tenure as Independent Director ended after 2.2 years in the role. We don't have any record of a personal shareholding under Xiaoming's name. A total of 2 executives have left over the last 12 months. The current median tenure of the management team is 3.42 years.Reported Earnings • Jul 16Third quarter 2021 earnings released: US$0.17 loss per share (vs US$0.098 loss in 3Q 2020)Third quarter 2021 results: Net loss: US$5.21m (loss widened 128% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has increased by 27% per year, which means it is tracking significantly ahead of earnings growth.Executive Departure • Jul 13CFO, Treasurer & Secretary Avraham Gabay has left the companyOn the 5th of July, Avraham Gabay's tenure as CFO, Treasurer & Secretary ended after 2.1 years in the role. We don't have any record of a personal shareholding under Avraham's name. Avraham is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 10.00 years.Reported Earnings • Apr 16Second quarter 2021 earnings released: US$0.17 loss per share (vs US$0.21 loss in 2Q 2020)Second quarter 2021 results: Net loss: US$4.61m (loss widened 25% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth.Is New 90 Day High Low • Feb 17New 90-day high: ₪36.50The company is up 326% from its price of ₪8.57 on 19 November 2020. The Israeli market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 20% over the same period.Is New 90 Day High Low • Jan 25New 90-day high: ₪21.96The company is up 160% from its price of ₪8.44 on 27 October 2020. The Israeli market is up 25% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 11% over the same period.Analyst Estimate Surprise Post Earnings • Jan 19Revenue beats expectationsRevenue exceeded analyst estimates by 1.3%. Over the next year, revenue is forecast to grow 29%, compared to a 240% growth forecast for the Pharmaceuticals industry in Israel.Reported Earnings • Jan 15First quarter 2021 earnings released: US$0.23 loss per shareFirst quarter 2021 results: Net loss: US$5.57m (loss widened 119% from 1Q 2020). Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings.Is New 90 Day High Low • Nov 30New 90-day high: ₪16.00The company is up 38% from its price of ₪11.56 on 01 September 2020. The Israeli market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 4.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₪149 per share.Reported Earnings • Nov 25Full year 2020 earnings released: US$0.56 loss per shareFull year 2020 results: Net loss: US$11.5m (loss narrowed 20% from FY 2019). Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 32% per year, which means it is significantly lagging earnings.Analyst Estimate Surprise Post Earnings • Nov 25Revenue misses expectationsRevenue missed analyst estimates by 31%. Over the next year, revenue is forecast to grow 32%, compared to a 77% growth forecast for the Pharmaceuticals industry in Israel.Is New 90 Day High Low • Oct 26New 90-day low: ₪8.64The company is down 35% from its price of ₪13.33 on 28 July 2020. The Israeli market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₪141 per share.Is New 90 Day High Low • Sep 30New 90-day low: ₪9.45The company is down 20% from its price of ₪11.81 on 02 July 2020. The Israeli market is up 2.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 25% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₪152 per share.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 ORMP 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: ORMP 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Oramed Pharmaceuticals 배당 수익률 vs 시장ORMP의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (ORMP)6.9%시장 하위 25% (IL)1.8%시장 상위 25% (IL)5.8%업계 평균 (Pharmaceuticals)2.1%분석가 예측 (ORMP) (최대 3년)n/a주목할만한 배당금: ORMP 의 배당금( 6.94% )은 IL 시장에서 배당금 지급자의 하위 25%( 1.85% )보다 높습니다.고배당: ORMP 의 배당금( 6.94% )은 IL 시장( 5.77% )주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 ORMP 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: ORMP 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YIL 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/17 00:26종가2026/06/17 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Oramed Pharmaceuticals Inc.는 4명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Andrew D'SilvaB. Riley Securities, Inc.Edward NashCanaccord GenuityRobert LeBoyerLadenburg Thalmann & Company1명의 분석가 더 보기
공시 • Jan 08Oramed Pharmaceuticals Inc. Approves Cash Dividend Payable on January 26, 2026Oramed Pharmaceuticals Inc.'s Board of Directors approved a cash dividend payment of $0.25 per share. The dividend will have an ex-dividend date of January 16, 2026, with disbursement scheduled for January 26, 2026. The dividend is expected to result in an aggregate distribution of approximately $10.5 million based on the current number of shares outstanding. The dividend will be funded with surplus capital.
공시 • Nov 18Oramed Pharmaceuticals Inc. Declares Dividend Distribution of Common Stock, Payable on November 27, 2025The Board of Directors of Oramed Pharmaceuticals Inc. announced that it has unanimously adopted a Rights Agreement, dated November 17, 2025 (the "Rights Plan"), by and between the Company and Continental Stock Transfer & Trust Company, as rights agent, and declared a dividend of one common stock purchase right (a "Right") on each outstanding share of its common stock, par value $0.012 per share (the "Common Stock"), of the Company. The dividend distribution will be payable on November 27, 2025, to stockholders of record as of the close of business on November 27, 2025.
공시 • Jun 27Oramed Pharmaceuticals Inc. (NasdaqCM:ORMP) announces an Equity Buyback for $20 million worth of its shares.Oramed Pharmaceuticals Inc. (NasdaqCM:ORMP) announces a share repurchase program. Under the program, the company will repurchase up to $20 million worth of its shares. The program will expired in 12 months.
공시 • May 17Oramed Pharmaceuticals Inc. announced delayed 10-Q filingOn 05/15/2026, Oramed Pharmaceuticals Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
New Risk • Mar 29New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 189% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (189% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (7.9% average weekly change). Revenue is less than US$5m (US$2.0m revenue).
공시 • Mar 26Lifeward Ltd. (NasdaqCM:LFWD) completed the acquisition of Oratech Pharma, Inc. from Oramed Pharmaceuticals Inc. (NasdaqCM:ORMP).Lifeward Ltd. (NasdaqCM:LFWD) entered into a share purchase agreement to acquire Oratech Pharma, Inc. from Oramed Pharmaceuticals Inc. (NasdaqCM:ORMP) on January 12, 2026. At closing, the Company will issue ordinary shares and pre-funded warrants to Oramed Pharmaceuticals, Inc. in an amount representing 49.99% of the Company’s fully diluted equity capitalization, subject to certain adjustments and ownership limitations. The number of ordinary shares issued at closing is capped at 45% of Lifeward’s outstanding ordinary shares, with the balance issued in the form of pre-funded warrants. Approximately 5% of the equity consideration will be held back in the form of pre-funded warrants for indemnification purposes and released after 12 months, subject to claims. In addition, the Company will issue transaction warrants to purchase ordinary shares, with the number of warrants determined by dividing Lifeward’s net cash at closing by an exercise price of $0.45 per share. As further consideration, Lifeward agreed to make contingent quarterly revenue-sharing payments equal to 4% of net revenue from sales of ReWalk Personal Exoskeleton products and related warranties. The transaction is subject to approval by regulatory board / committee, approval of offer by acquirer shareholders, registration statement effectiveness (S-4 / F-4), lock-up agreement and listing / approval of new shares on stock exchange. The transaction has received unanimous approval from Lifeward’s board of directors. The transaction is contingent upon closing conditions. As of March 12, 2026, Lifeward Ltd. shareholders approved the transaction. Rachael M. Bushey and Jennifer Porter of Goodwin Procter LLP acted as legal advisor for Lifeward Ltd. Aaron M. Lampert and Ephraim P. Friedman of Goldfarb Seligman & Co. acted as legal advisor for Lifeward Ltd. Rick A. Werner, Alla Digilova, and Simin Sun of Haynes and Boone, LLP acted as legal advisor for Oramed Pharmaceuticals Inc. Lifeward Ltd. (NasdaqCM:LFWD) completed the acquisition of Oratech Pharma, Inc. from Oramed Pharmaceuticals Inc. (NasdaqCM:ORMP) on March 25, 2026. At closing, Lifeward issued an aggregate 2,256,476 shares of its ordinary shares and pre-funded warrants. Lifeward also issued 1,296,296 warrants to purchase Oratech Pharma's ordinary shares.
Valuation Update With 7 Day Price Move • Jan 08Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₪10.58, the stock trades at a trailing P/E ratio of 3x. Average trailing P/E is 24x in the Pharmaceuticals industry in Asia. Total returns to shareholders of 19% over the past three years.
공시 • Jan 08Oramed Pharmaceuticals Inc. Approves Cash Dividend Payable on January 26, 2026Oramed Pharmaceuticals Inc.'s Board of Directors approved a cash dividend payment of $0.25 per share. The dividend will have an ex-dividend date of January 16, 2026, with disbursement scheduled for January 26, 2026. The dividend is expected to result in an aggregate distribution of approximately $10.5 million based on the current number of shares outstanding. The dividend will be funded with surplus capital.
공시 • Jan 01Oramed Pharmaceuticals Inc. Announces Resignation of Leonard Sank from the Board, Effective as of January 1, 2026On December 31, 2025, the board of directors (the “Board”) of Oramed Pharmaceuticals Inc. (the “Company”) received notice of Leonard Sank’s intention to resign from the Board, effective as of January 1, 2026. Mr. Sank’s resignation did not result from any disagreement with the Company on any matter relating to the Company’s operations, policies or practices. Mr. Sank served 18 years at the Company.
Valuation Update With 7 Day Price Move • Dec 14Investor sentiment improves as stock rises 20%After last week's 20% share price gain to ₪10.33, the stock trades at a trailing P/E ratio of 2.8x. Average forward P/E is 20x in the Pharmaceuticals industry in Asia. Total loss to shareholders of 62% over the past three years.
New Risk • Nov 19New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Israeli stocks, typically moving 6.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (135% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (6.1% average weekly change). Revenue is less than US$5m (US$2.0m revenue). Market cap is less than US$100m (₪324.5m market cap, or US$99.1m).
공시 • Nov 18Oramed Pharmaceuticals Inc. Declares Dividend Distribution of Common Stock, Payable on November 27, 2025The Board of Directors of Oramed Pharmaceuticals Inc. announced that it has unanimously adopted a Rights Agreement, dated November 17, 2025 (the "Rights Plan"), by and between the Company and Continental Stock Transfer & Trust Company, as rights agent, and declared a dividend of one common stock purchase right (a "Right") on each outstanding share of its common stock, par value $0.012 per share (the "Common Stock"), of the Company. The dividend distribution will be payable on November 27, 2025, to stockholders of record as of the close of business on November 27, 2025.
공시 • Jul 17Oramed Pharmaceuticals Inc., Annual General Meeting, Aug 19, 2025Oramed Pharmaceuticals Inc., Annual General Meeting, Aug 19, 2025. Location: proskauer rose llp, one boca place, 2255 glades road, suite 421 atrium, fl 33431-7360, boca raton United States
Board Change • Jul 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 7 highly experienced directors. Member of Scientific Advisory Board Anne Peters was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
New Risk • Apr 06New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Israeli stocks, typically moving 8.0% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.0% average weekly change). Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable next year (US$2.8m net loss next year). Market cap is less than US$100m (₪321.2m market cap, or US$85.8m).
New Risk • Mar 29New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next year. Trailing 12-month net loss: US$19m Forecast net loss in 1 year: US$4.7m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable next year (US$4.7m net loss next year). Share price has been volatile over the past 3 months (7.7% average weekly change). Market cap is less than US$100m (₪329.4m market cap, or US$89.1m).
Valuation Update With 7 Day Price Move • Mar 09Investor sentiment improves as stock rises 25%After last week's 25% share price gain to ₪9.16, the stock trades at a trailing P/E ratio of 23.2x. Average forward P/E is 18x in the Pharmaceuticals industry in Asia. Total loss to shareholders of 69% over the past three years.
New Risk • Feb 12New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Israeli stocks, typically moving 5.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 104% per year for the foreseeable future. High level of non-cash earnings (40% accrual ratio). Revenue is less than US$1m. Minor Risk Share price has been volatile over the past 3 months (5.8% average weekly change).
Valuation Update With 7 Day Price Move • Feb 12Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₪9.34, the stock trades at a trailing P/E ratio of 23.5x. Average forward P/E is 18x in the Pharmaceuticals industry in Asia. Total loss to shareholders of 75% over the past three years.
New Risk • Aug 17New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 188% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.9% average weekly change). Earnings are forecast to decline by an average of 198% per year for the foreseeable future. High level of non-cash earnings (188% accrual ratio). Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (₪348.7m market cap, or US$95.1m).
New Risk • Jul 31New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₪371.5m (US$98.7m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.7% average weekly change). Earnings are forecast to decline by an average of 169% per year for the foreseeable future. Revenue is less than US$1m (US$674k revenue). Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (₪371.5m market cap, or US$98.7m).
Valuation Update With 7 Day Price Move • Jun 27Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₪9.79, the stock trades at a trailing P/E ratio of 10x. Average forward P/E is 18x in the Pharmaceuticals industry in Asia. Total loss to shareholders of 77% over the past three years.
공시 • Jun 27Oramed Pharmaceuticals Inc. (NasdaqCM:ORMP) announces an Equity Buyback for $20 million worth of its shares.Oramed Pharmaceuticals Inc. (NasdaqCM:ORMP) announces a share repurchase program. Under the program, the company will repurchase up to $20 million worth of its shares. The program will expired in 12 months.
공시 • Jun 22Oramed Pharmaceuticals Inc., Annual General Meeting, Aug 01, 2024Oramed Pharmaceuticals Inc., Annual General Meeting, Aug 01, 2024. Location: 20 mamilla avenue, israel 9414904, jerusalem Israel
공시 • Jun 13+ 1 more updateOramed Pharmaceuticals Inc. Appoints Mr. Avraham Gabay as Treasurer and Secretary, Effective as of June 18, 2024On June 6, 2024, Oramed Pharmaceuticals Inc. appointed Mr. Avraham Gabay to serve as Treasurer and Secretary of the Company, effective as of June 18, 2024. Prior to his appointment, Mr. Gabay served as interim chief financial officer of BiomX Inc. since 2023. From 2021 until 2023, Mr. Gabay served as the chief financial officer at Oravax Inc., a 63% owned subsidiary of the Company. From 2019 until 2021, Mr. Gabay was the chief financial officer of the Company. From 2015 to 2019, Mr. Gabay served as VP Finance at Orcam Technologies Ltd. From 2014 to 2015, Mr. Gabay provided economic services in the advisory department of KPMG Israel, a certified public accounting firm, and from 2013 to 2014, he worked in the tax department of the law firm Gornitzky & Co. In addition, Mr. Gabay serves as a director on the board of Iintoo Ltd. Mr. Gabay holds a bachelor’s degree in law and accounting (magna cum-laude) from Tel-Aviv University and is a certified public accountant in Israel and a member of the Israeli Bar Association.
New Risk • May 20New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 95% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.5% average weekly change). Earnings are forecast to decline by an average of 95% per year for the foreseeable future. Revenue is less than US$1m (US$674k revenue). Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (₪345.9m market cap, or US$93.4m).
Reported Earnings • May 12First quarter 2024 earnings released: EPS: US$0.038 (vs US$0.085 loss in 1Q 2023)First quarter 2024 results: EPS: US$0.038 (up from US$0.085 loss in 1Q 2023). Net income: US$1.54m (up US$4.93m from 1Q 2023). Over the last 3 years on average, earnings per share has increased by 46% per year but the company’s share price has fallen by 36% per year, which means it is significantly lagging earnings.
New Risk • Apr 16New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₪369.9m (US$98.1m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risks Large one-off items impacting financial results. Revenue is less than US$5m (US$1.3m revenue). Market cap is less than US$100m (₪369.9m market cap, or US$98.1m).
공시 • Mar 19Oramed Pharmaceuticals Inc. has filed a Follow-on Equity Offering in the amount of $75 million.Oramed Pharmaceuticals Inc. has filed a Follow-on Equity Offering in the amount of $75 million. Security Name: COMMON STOCK Security Type: Common Stock Transaction Features: At the Market Offering
Reported Earnings • Mar 07Full year 2023 earnings released: EPS: US$0.14 (vs US$0.94 loss in FY 2022)Full year 2023 results: EPS: US$0.14 (up from US$0.94 loss in FY 2022). Net income: US$5.53m (up US$42.1m from FY 2022). Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings.
New Risk • Jan 31New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Israeli stocks, typically moving 9.2% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.2% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable next year (US$11m net loss next year). Shareholders have been diluted in the past year (3.1% increase in shares outstanding). Revenue is less than US$5m (US$2.0m revenue).
Board Change • Jan 23Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 5 highly experienced directors. Member of Scientific Advisory Board Jay Skyler was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
공시 • Dec 19Oramed Pharmaceuticals Inc. Appoints Daniel Aghion as Director, Effective January 1, 2024On December 18, 2023, Oramed Pharmaceuticals Inc. (Company) increased the size of its Board of Directors by one and appointed Dr. Daniel Aghion to serve as a director to fill the resulting vacancy, effective as of January 1, 2024. The Board has not yet taken action to appoint Dr. Aghion to any committees of the Board. Dr. Daniel Aghion, age 42, is a neurosurgeon at Memorial Neuroscience Institute in Florida since 2016, where he treats patients with a wide array of spine disorders, including severe degenerative spine diseases, spine trauma, cancer in the spine, spine tumors, peripheral nerve surgery and more. Dr. Aghion holds a Bachelor's of Science degree from the University of Michigan and an MD from the Sackler School of Medicine at Tel Aviv University. He completed his residency at Rhode Island Hospital in 2015, and a complex spine fellowship at Johns Hopkins University in Baltimore in 2016.
Reported Earnings • Nov 11Third quarter 2023 earnings released: US$0.08 loss per share (vs US$0.18 loss in 3Q 2022)Third quarter 2023 results: US$0.08 loss per share (improved from US$0.18 loss in 3Q 2022). Net loss: US$3.22m (loss narrowed 54% from 3Q 2022). Revenue is expected to decline by 70% p.a. on average during the next 2 years, while revenues in the Pharmaceuticals industry in Asia are expected to grow by 11%. Over the last 3 years on average, earnings per share has remained flat whereas the company’s share price has fallen by 5% per year.
New Risk • Oct 05New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₪357.4m (US$93.0m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 21% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$47m net loss in 3 years). Share price has been volatile over the past 3 months (6.8% average weekly change). Shareholders have been diluted in the past year (3.7% increase in shares outstanding). Revenue is less than US$5m (US$2.7m revenue). Market cap is less than US$100m (₪357.4m market cap, or US$93.0m).
Reported Earnings • Aug 11Second quarter 2023 earnings released: US$0.03 loss per share (vs US$0.27 loss in 2Q 2022)Second quarter 2023 results: US$0.03 loss per share (improved from US$0.27 loss in 2Q 2022). Net loss: US$1.19m (loss narrowed 89% from 2Q 2022). Revenue is expected to decline by 84% p.a. on average during the next 3 years, while revenues in the Pharmaceuticals industry in Asia are expected to grow by 9.8%. Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has only fallen by 3% per year, which means it has not declined as severely as earnings.
공시 • Aug 09Oramed Pharmaceuticals Inc. (NasdaqCM:ORMP) entered into a Stalking Horse Stock Purchase Term Sheet to acquire a 40.17% stake in Scilex Holding Company (NasdaqCM:SCLX) from Sorrento Therapeutics, Inc. (OTCPK:SRNE.Q) for approximately $110 million.Oramed Pharmaceuticals Inc. (NasdaqCM:ORMP) entered into a Stalking Horse Stock Purchase Term Sheet to acquire a 40.17% stake in Scilex Holding Company (NasdaqCM:SCLX) from Sorrento Therapeutics, Inc. (OTCPK:SRNE.Q) for approximately $110 million on August 4, 2023. Oramed Pharmaceuticals Inc. entered into a Stalking Horse Agreement to acquire a 40.17% stake in Scilex Holding Company from Sorrento Therapeutics, Inc. on August 8, 2023. Oramed to purchase 59,726,737 shares of common stock of Scilex and 29,057,096 shares of Series A preferred stock of Scilex under the transaction. As a part of consideration, Oramed will provide a non-amortizing super-priority debtor-in-possession term loan financing facility in an aggregate principal amount of $100 million (the “Replacement DIP Facility”) and remaining consideration in cash. Oramed Pharmaceuticals Inc. will receive a a break-up fee in the amount of $3,412,500, in case of termmination. Oramed will be capitalized with sufficient debt and equity capital to fund the cash portion of the Purchase Price. Term Sheet is subject to a final definitive documentation to be negotiated in good faith between the parties, uthorization and approval by the United States Bankruptcy Court for the Southern District of Texas,all HSR filing and waiting periods applicable to the Sale shall have expired or been terminated, all other governmental and regulatory approvals, if any, shall have been obtained, parties shall have entered into a new Registration Rights Agreement, approval of board of directors of Scilex and satisfaction or waiver of the other Closing Conditions. The proposed transaction will not be subject to a financing contingency. The stalking horse agreement with Oramed is subject to an auction and the submission of higher or otherwise better offers. Any parties interested in bidding for the Scilex Stock should email Sorrento's investment banker (Moelis & Company LLC) as soon as possible to indicate their interest and discuss required bid materials. To the extent Sorrento receives any qualified bids that are higher or otherwise better than Oramed's bid by August 11, 2023, at 5:00 p.m. (ET), Sorrento will hold an auction for the Scilex Stock on August 14, 2023. The U.S. Bankruptcy Court for the Southern District of Texas (the "Bankruptcy Court") approved the transaction on August 8, 2023. Transaction is expected to be completed by or before September 15, 2023. Latham & Watkins LLP and Jackson Walker LLP are serving as legal counsel to Sorrento. M3 Partners is serving as restructuring advisor. Moelis & Company LLC is serving as financial advisor and investment banker. H.C. Wainwright & Co. acted as financial and capital markets advisor to Oramed.
공시 • Jul 12Oramed Pharmaceuticals Inc., Annual General Meeting, Jul 13, 2023Oramed Pharmaceuticals Inc., Annual General Meeting, Jul 13, 2023, at 16:00 Israel Standard Time. Location: 20 Mamilla Avenue Jerusalem Israel Agenda: To consider and re-elect six directors of the Company to hold office until next annual meeting of stockholders and until their respective successors shall be elected and qualified or until their earlier resignation or removal; to consider and ratify the appointment of Kesselman & Kesselman, certified public accountants in Israel, a member of PricewaterhouseCoopers International Limited as the independent registered public accounting firm of the Company for the 2023 fiscal year; and to transact any other business as may properly come before the Annual Meeting or any adjournments thereof.
Reported Earnings • May 13First quarter 2023 earnings released: US$0.085 loss per share (vs US$0.27 loss in 1Q 2022)First quarter 2023 results: US$0.085 loss per share (improved from US$0.27 loss in 1Q 2022). Net loss: US$3.40m (loss narrowed 67% from 1Q 2022). Revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Asia. Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has only fallen by 3% per year, which means it has not declined as severely as earnings.
Recent Insider Transactions • Apr 06Independent Director recently bought ₪70k worth of stockOn the 4th of April, Arie Mayer bought around 9k shares on-market at roughly ₪7.94 per share. This transaction amounted to 49% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger purchase from another insider worth ₪729k. Insiders have collectively bought ₪406k more in shares than they have sold in the last 12 months.
Recent Insider Transactions • Mar 16Independent Director recently bought ₪513k worth of stockOn the 14th of March, Yadin Rozov bought around 70k shares on-market at roughly ₪7.33 per share. This transaction increased Yadin's direct individual holding by 4x at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought ₪211k more in shares than they have sold in the last 12 months.
Reported Earnings • Mar 08Full year 2022 earnings released: US$0.94 loss per share (vs US$0.94 loss in FY 2021)Full year 2022 results: US$0.94 loss per share. Net loss: US$36.6m (loss widened 4.4% from FY 2021). Revenue is forecast to grow 26% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Pharmaceuticals industry in Asia.
공시 • Jan 12Oramed Pharmaceuticals Inc. Announces Top-Line Results from Phase 3 Trial of ORMD-0801 for the Treatment of Type 2 DiabetesOramed Pharmaceuticals Inc. announced top-line results from its Phase 3 randomized, double-blind, placebo-controlled, multicenter clinical trial (ORA-D-013-1) comparing the efficacy of ORMD-0801 to placebo in patients with Type 2 Diabetes (T2D) at 26 weeks. ORA-D-013-1 enrolled 710 patients with T2D and inadequate glycemic control on two or three oral glucose-lowering agents. The ORA-D-013-1 trial did not meet its primary endpoint, which compared the efficacy of ORMD-0801 to placebo in improving glycemic control as assessed by the mean change from baseline in A1C at 26 weeks. The trial also did not meet its secondary endpoint, which assessed the mean change from baseline in fasting plasma glucose at 26 weeks. There were no serious drug-related adverse events. Therefore, Oramed expects to discontinue its oral insulin clinical activities for T2D. Additional Information About the ORA-D-013-1 Phase 3 Clinical Trial: In the ORA-D-013-1 trial, patients were randomized 2:2:1:1 into four groups: 8 mg dosed once-daily; 8 mg dosed twice-daily; placebo dosed once-daily; and placebo dosed twice-daily. Patients completed an initial 21-day Screening Period, followed by a 26-week Double-Blind Treatment Period.
공시 • Jan 05Oramed Pharmaceuticals Inc. Granted U.S. Combination Therapy Patent for Oral Glp-1 & Insulin for the Treatment of DiabetesOramed Pharmaceuticals Inc. announced that the United States Patent and Trademark Office has granted the Company a patent titled "Methods and Compositions for Treating Diabetes." The patent serves as an extension to a patent previously granted in May 2022 and addresses methods and compositions for treating diabetes mellitus through oral pharmaceutical compositions comprising insulin in combination with Glucagon-like Peptide 1 (GLP-1).
Board Change • Nov 16High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 2 experienced directors. 5 highly experienced directors. Chief Scientific Officer & Director Miriam Kidron is the most experienced director on the board, commencing their role in 2006. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
Reported Earnings • Nov 12Third quarter 2022 earnings released: US$0.18 loss per share (vs US$0.21 loss in 3Q 2021)Third quarter 2022 results: US$0.18 loss per share. Net loss: US$7.06m (loss widened 3.0% from 3Q 2021). Revenue is forecast to grow 86% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Asia.
Reported Earnings • Aug 11Second quarter 2022 earnings released: US$0.27 loss per share (vs US$0.17 loss in 2Q 2021)Second quarter 2022 results: US$0.27 loss per share (down from US$0.17 loss in 2Q 2021). Net loss: US$10.5m (loss widened 102% from 2Q 2021). Over the next year, revenue is forecast to grow 6.4%, compared to a 24% growth forecast for the industry in Israel. Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has increased by 38% per year, which means it is well ahead of earnings.
Board Change • Jul 15High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 2 experienced directors. 5 highly experienced directors. Chief Scientific Officer & Director Miriam Kidron is the most experienced director on the board, commencing their role in 2006. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
Reported Earnings • May 14First quarter 2022 earnings released: US$0.27 loss per share (vs US$0.17 loss in 1Q 2021)First quarter 2022 results: US$0.27 loss per share (down from US$0.17 loss in 1Q 2021). Net loss: US$10.4m (loss widened 126% from 1Q 2021). Over the next year, revenue is forecast to grow 2.5%, compared to a 23% growth forecast for the industry in Israel. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has increased by 6% per year, which means it is well ahead of earnings.
Reported Earnings • Apr 02Full year 2021 earnings released: US$0.94 loss per share (vs US$0.90 loss in FY 2020)Full year 2021 results: US$0.94 loss per share (down from US$0.90 loss in FY 2020). Net loss: US$35.0m (loss widened 59% from FY 2020). Over the next year, revenue is forecast to grow 1.4%, compared to a 21% growth forecast for the pharmaceuticals industry in Israel. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has increased by 30% per year, which means it is tracking significantly ahead of earnings growth.
Recent Insider Transactions • Mar 29Independent Chairman of the Board recently sold ₪303k worth of stockOn the 21st of March, Kevin Rakin sold around 10k shares on-market at roughly ₪30.28 per share. This was the largest sale by an insider in the last 3 months. Kevin has been a seller over the last 12 months, reducing personal holdings by ₪1.7m.
Reported Earnings • Jan 12First quarter 2022 earnings: EPS in line with expectations, revenues disappointFirst quarter 2022 results: US$0.21 loss per share (up from US$0.23 loss in 1Q 2021). Net loss: US$7.89m (loss widened 42% from 1Q 2021). Revenue missed analyst estimates by 3.7%. Over the next year, revenue is forecast to grow 2.2%, compared to a 22% growth forecast for the industry in Israel. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has increased by 45% per year, which means it is tracking significantly ahead of earnings growth.
Reported Earnings • Nov 25Full year 2021 earnings: EPS in line with expectations, revenues disappointFull year 2021 results: US$0.78 loss per share (down from US$0.56 loss in FY 2020). Net loss: US$22.2m (loss widened 93% from FY 2020). Revenue missed analyst estimates by 9.2%. Over the next year, revenue is forecast to stay flat compared to a 23% growth forecast for the pharmaceuticals industry in Israel. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has increased by 62% per year, which means it is tracking significantly ahead of earnings growth.
Recent Insider Transactions • Sep 22Independent Chairman of the Board recently sold ₪1.4m worth of stockOn the 16th of September, Kevin Rakin sold around 21k shares on-market at roughly ₪67.43 per share. This was the largest sale by an insider in the last 3 months. This was Kevin's only on-market trade for the last 12 months.
Executive Departure • Sep 03Independent Director Xiaoming Gao has left the companyOn the 30th of August, Xiaoming Gao's tenure as Independent Director ended after 2.2 years in the role. We don't have any record of a personal shareholding under Xiaoming's name. A total of 2 executives have left over the last 12 months. The current median tenure of the management team is 3.42 years.
Reported Earnings • Jul 16Third quarter 2021 earnings released: US$0.17 loss per share (vs US$0.098 loss in 3Q 2020)Third quarter 2021 results: Net loss: US$5.21m (loss widened 128% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has increased by 27% per year, which means it is tracking significantly ahead of earnings growth.
Executive Departure • Jul 13CFO, Treasurer & Secretary Avraham Gabay has left the companyOn the 5th of July, Avraham Gabay's tenure as CFO, Treasurer & Secretary ended after 2.1 years in the role. We don't have any record of a personal shareholding under Avraham's name. Avraham is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 10.00 years.
Reported Earnings • Apr 16Second quarter 2021 earnings released: US$0.17 loss per share (vs US$0.21 loss in 2Q 2020)Second quarter 2021 results: Net loss: US$4.61m (loss widened 25% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth.
Is New 90 Day High Low • Feb 17New 90-day high: ₪36.50The company is up 326% from its price of ₪8.57 on 19 November 2020. The Israeli market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 20% over the same period.
Is New 90 Day High Low • Jan 25New 90-day high: ₪21.96The company is up 160% from its price of ₪8.44 on 27 October 2020. The Israeli market is up 25% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 11% over the same period.
Analyst Estimate Surprise Post Earnings • Jan 19Revenue beats expectationsRevenue exceeded analyst estimates by 1.3%. Over the next year, revenue is forecast to grow 29%, compared to a 240% growth forecast for the Pharmaceuticals industry in Israel.
Reported Earnings • Jan 15First quarter 2021 earnings released: US$0.23 loss per shareFirst quarter 2021 results: Net loss: US$5.57m (loss widened 119% from 1Q 2020). Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings.
Is New 90 Day High Low • Nov 30New 90-day high: ₪16.00The company is up 38% from its price of ₪11.56 on 01 September 2020. The Israeli market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 4.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₪149 per share.
Reported Earnings • Nov 25Full year 2020 earnings released: US$0.56 loss per shareFull year 2020 results: Net loss: US$11.5m (loss narrowed 20% from FY 2019). Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 32% per year, which means it is significantly lagging earnings.
Analyst Estimate Surprise Post Earnings • Nov 25Revenue misses expectationsRevenue missed analyst estimates by 31%. Over the next year, revenue is forecast to grow 32%, compared to a 77% growth forecast for the Pharmaceuticals industry in Israel.
Is New 90 Day High Low • Oct 26New 90-day low: ₪8.64The company is down 35% from its price of ₪13.33 on 28 July 2020. The Israeli market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₪141 per share.
Is New 90 Day High Low • Sep 30New 90-day low: ₪9.45The company is down 20% from its price of ₪11.81 on 02 July 2020. The Israeli market is up 2.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 25% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₪152 per share.